MX2018011383A - Replicon de arn para la expresion genica versatil y eficiente. - Google Patents
Replicon de arn para la expresion genica versatil y eficiente.Info
- Publication number
- MX2018011383A MX2018011383A MX2018011383A MX2018011383A MX2018011383A MX 2018011383 A MX2018011383 A MX 2018011383A MX 2018011383 A MX2018011383 A MX 2018011383A MX 2018011383 A MX2018011383 A MX 2018011383A MX 2018011383 A MX2018011383 A MX 2018011383A
- Authority
- MX
- Mexico
- Prior art keywords
- rna replicon
- protein
- alphavirus
- replicase
- replication
- Prior art date
Links
- 230000014509 gene expression Effects 0.000 title abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 7
- 241000710929 Alphavirus Species 0.000 abstract 6
- 230000010076 replication Effects 0.000 abstract 5
- 108010026228 mRNA guanylyltransferase Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 108091081024 Start codon Proteins 0.000 abstract 2
- 101710172711 Structural protein Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000014616 translation Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
La presente invención abarca un replicón de ARN que puede replicarse mediante una replicasa de origen de alfavirus. El replicón de ARN comprende elementos de secuencia requeridos para la replicación mediante la replicasa, pero estos elementos de secuencia no codifican ninguna proteína o fragmento de la misma, tales como una proteína no estructural de alfavirus o un fragmento de la misma. De este modo, en el replicón de ARN de conformidad con la invención, los elementos de secuencia requeridos para la replicación mediante la replicasa y la o las regiones codificadoras de proteína están desacoplados. De acuerdo con la presente invención, el desacoplamiento se consigue mediante la eliminación de al menos un codón de iniciación en comparación con un ARN genómico de alfavirus nativo. En particular, el replicón de ARN comprende una secuencia de reconocimiento de replicación 5', en donde la secuencia de reconocimiento de replicación 5' se caracteriza porque comprende la eliminación de al menos un codón de iniciación en comparación con una secuencia de reconocimiento de replicación 5' de alfavirus nativo. La replicasa de origen de alfavirus puede estar codificada por un marco de lectura abierto en el replicón de ARN o en una molécula de ARN separada. La presente invención permite la expresión eficiente y segura de una proteína de interés en una célula u organismo, pero no está asociada con la producción no deseada de fragmentos de proteína no estructural de alfavirus. En la presente se proporcionan métodos de producción de proteínas in vitro e in vivo, así como usos médicos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2016/056165 WO2017162266A1 (en) | 2016-03-21 | 2016-03-21 | Rna replicon for versatile and efficient gene expression |
| PCT/EP2017/055808 WO2017162460A1 (en) | 2016-03-21 | 2017-03-13 | Rna replicon for versatile and efficient gene expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018011383A true MX2018011383A (es) | 2019-02-13 |
Family
ID=55587284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018011383A MX2018011383A (es) | 2016-03-21 | 2017-03-13 | Replicon de arn para la expresion genica versatil y eficiente. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11168337B2 (es) |
| EP (2) | EP3433369B1 (es) |
| JP (2) | JP7121443B2 (es) |
| KR (1) | KR102161607B1 (es) |
| CN (2) | CN108884473B (es) |
| AU (1) | AU2017236239B2 (es) |
| BR (1) | BR112018068381A2 (es) |
| CA (1) | CA3017272A1 (es) |
| CY (1) | CY1125086T1 (es) |
| DK (2) | DK3433369T3 (es) |
| ES (2) | ES2784711T3 (es) |
| HK (1) | HK1259449A1 (es) |
| HR (1) | HRP20220044T1 (es) |
| HU (2) | HUE050350T2 (es) |
| IL (2) | IL261379B (es) |
| LT (1) | LT3701959T (es) |
| MX (1) | MX2018011383A (es) |
| PL (2) | PL3701959T3 (es) |
| PT (2) | PT3433369T (es) |
| RS (1) | RS62864B1 (es) |
| RU (1) | RU2748892C2 (es) |
| SG (1) | SG11201807374WA (es) |
| SI (2) | SI3433369T1 (es) |
| WO (2) | WO2017162266A1 (es) |
| ZA (1) | ZA201805519B (es) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
| WO2019053012A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Rna Pharmaceuticals Gmbh | RNA REPLICON FOR THE REPROGRAMMING OF SOMATIC CELLS |
| CA3074919A1 (en) * | 2017-09-13 | 2019-03-21 | Biontech Cell & Gene Therapies Gmbh | Rna replicon for expressing a t cell receptor or an artificial t cell receptor |
| CN113573729A (zh) | 2019-01-10 | 2021-10-29 | 詹森生物科技公司 | 前列腺新抗原及其用途 |
| WO2020252093A1 (en) * | 2019-06-10 | 2020-12-17 | Infectious Disease Research Institute | Methods and compositions of astrovirus replicons |
| WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
| IL293051A (en) | 2019-11-18 | 2022-07-01 | Janssen Biotech Inc | calr and jak2 mutant-based vaccines and their uses |
| CN110890127B (zh) * | 2019-11-27 | 2024-02-23 | 山东大学 | 酿酒酵母dna复制起始区域识别方法 |
| WO2021138447A1 (en) | 2019-12-31 | 2021-07-08 | Elixirgen Therapeutics, Inc. | Temperature-based transient delivery of nucleic acids and proteins to cells and tissues |
| WO2021160346A1 (en) | 2020-02-13 | 2021-08-19 | Institut Pasteur | Nucleic acid vaccine against the sars-cov-2 coronavirus |
| US11759515B2 (en) * | 2020-03-09 | 2023-09-19 | Arcturus Therapeutics, Inc. | Compositions and methods for inducing immune responses |
| GB202307565D0 (en) * | 2020-04-22 | 2023-07-05 | BioNTech SE | Coronavirus vaccine |
| AU2021271300A1 (en) * | 2020-05-11 | 2023-02-02 | Janssen Pharmaceuticals, Inc. | RNA replicon encoding a stabilized corona virus spike protein |
| CA3181193A1 (en) * | 2020-06-04 | 2021-12-09 | Mario Perkovic | Rna replicon for versatile and efficient gene expression |
| GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
| US11613561B2 (en) | 2021-03-19 | 2023-03-28 | Tiba Biotech, Llc | Artificial alphavirus-derived RNA replicon expression systems |
| JP2024518335A (ja) | 2021-04-26 | 2024-05-01 | アンスティチュ パスツール | ＳＡＲＳ－ＣｏＶ－２に対するヒト中和モノクローナル抗体、及びそれらの使用 |
| WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
| TW202334196A (zh) | 2021-10-07 | 2023-09-01 | 英商阿法克塔生命科學有限公司 | Pd-l1結合多肽 |
| EP4412711A1 (en) | 2021-10-07 | 2024-08-14 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
| EP4419695A1 (en) | 2021-10-18 | 2024-08-28 | BioNTech SE | Modified replicable rna and related compositions and their use |
| EP4419708A1 (en) | 2021-10-18 | 2024-08-28 | BioNTech SE | Methods for determining mutations for increasing modified replicable rna function and related compositions and their use |
| EP4286003A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169580A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4186528A1 (en) | 2021-11-30 | 2023-05-31 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4401789A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4401788A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286004A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4402150A1 (en) | 2021-10-22 | 2024-07-24 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067121A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Oligosaccharide compounds and complexes |
| EP4169579A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4169534A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4285933A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4169578A1 (en) | 2021-10-22 | 2023-04-26 | BioNTech SE | Oligosaccharide compounds and complexes |
| WO2023067124A1 (en) | 2021-10-22 | 2023-04-27 | BioNTech SE | Disulfide oligosaccharide compounds and complexes |
| EP4285932A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide complexes and uses |
| EP4286394A1 (en) | 2022-05-30 | 2023-12-06 | BioNTech SE | Oligosaccharide compounds and complexes |
| KR20230121575A (ko) | 2022-02-10 | 2023-08-18 | 주식회사 아피셀테라퓨틱스 | Cd40l에 특이적으로 결합하는 스테핀 a 단백질 변이체 및 이의 용도 |
| CN114639442B (zh) * | 2022-03-30 | 2024-01-30 | 中国农业科学院农业基因组研究所 | 一种基于单核苷酸多态性预测开放阅读框的方法及系统 |
| WO2023213378A1 (en) | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
| WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2024056856A1 (en) | 2022-09-15 | 2024-03-21 | BioNTech SE | Systems and compositions comprising trans-amplifying rna vectors with mirna |
| WO2024068674A1 (en) | 2022-09-26 | 2024-04-04 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024084462A1 (en) | 2022-10-21 | 2024-04-25 | BioNTech SE | Nucleic acid complexes and uses thereof |
| WO2024176192A1 (en) | 2023-02-24 | 2024-08-29 | BioNTech SE | Immunogenic compositions |
| EP4442276A1 (en) | 2023-04-07 | 2024-10-09 | Institut Pasteur | Combined antibodies against sarbecoviruses and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ514055A (en) | 1999-03-09 | 2001-09-28 | Univ Florida | Multiple component RNA vector system for expression of foreign sequences |
| ES2330202T5 (es) | 2001-09-06 | 2014-01-20 | Alphavax, Inc. | Sistemas vectores basados en replicones de alfavirus |
| DK1608762T3 (da) * | 2003-03-20 | 2014-04-07 | Alphavax Inc | Forbedrede alphavirusreplikoner og hjælperkonstrukter |
| WO2008119827A1 (en) * | 2007-04-02 | 2008-10-09 | Fit Biotech Oy | Transreplicase constructs |
| WO2008157688A2 (en) | 2007-06-19 | 2008-12-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse phosphorothioate analogs of the messenger rna cap |
| US7850977B2 (en) * | 2007-06-21 | 2010-12-14 | Alphavax, Inc. | Promoterless cassettes for expression of alphavirus structural proteins |
| KR101637533B1 (ko) | 2007-08-20 | 2016-07-11 | 글락소 그룹 리미티드 | 제조 방법 |
| PL215513B1 (pl) | 2008-06-06 | 2013-12-31 | Univ Warszawski | Nowe boranofosforanowe analogi dinukleotydów, ich zastosowanie, czasteczka RNA, sposób otrzymywania RNA oraz sposób otrzymywania peptydów lub bialka |
| DE102008061522A1 (de) | 2008-12-10 | 2010-06-17 | Biontech Ag | Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung |
| EP2281579A1 (en) | 2009-08-05 | 2011-02-09 | BioNTech AG | Vaccine composition comprising 5'-Cap modified RNA |
| WO2012006378A1 (en) | 2010-07-06 | 2012-01-12 | Novartis Ag | Liposomes with lipids having an advantageous pka- value for rna delivery |
| ES2649896T3 (es) | 2010-07-06 | 2018-01-16 | Glaxosmithkline Biologicals Sa | Emulsiones catiónicas de aceite en agua |
| ES2939732T3 (es) | 2010-08-31 | 2023-04-26 | Glaxosmithkline Biologicals Sa | Liposomas pequeños para la administración de ARN que codifica para inmunógeno |
| DK2611461T3 (da) | 2010-08-31 | 2022-05-16 | Glaxosmithkline Biologicals Sa | Pegylerede liposomer til afgivelse af RNA, der koder immunogen |
| AU2011295938B2 (en) | 2010-08-31 | 2016-01-14 | Glaxosmithkline Biologicals S.A. | Lipids suitable for liposomal delivery of protein-coding RNA |
| WO2012051211A2 (en) * | 2010-10-11 | 2012-04-19 | Novartis Ag | Antigen delivery platforms |
| CA2840965C (en) | 2011-07-06 | 2021-03-02 | Novartis Ag | Cationic oil-in-water emulsions |
| EP4014966A1 (en) | 2011-07-06 | 2022-06-22 | GlaxoSmithKline Biologicals S.A. | Liposomes having useful n:p ratio for delivery of rna molecules |
| EP2729125B1 (en) | 2011-07-06 | 2017-12-13 | GlaxoSmithKline Biologicals SA | Oil-in-water emulsions that contain nucleic acids |
| SI2750707T1 (sl) | 2011-08-31 | 2019-02-28 | Glaxosmithkline Biologicals Sa | Pegilirani liposomi za dostavo imunogen-kodirajoče RNA |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| WO2014071963A1 (en) | 2012-11-09 | 2014-05-15 | Biontech Ag | Method for cellular rna expression |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
-
2016
- 2016-03-21 WO PCT/EP2016/056165 patent/WO2017162266A1/en active Application Filing
-
2017
- 2017-03-13 SG SG11201807374WA patent/SG11201807374WA/en unknown
- 2017-03-13 KR KR1020187027294A patent/KR102161607B1/ko active IP Right Grant
- 2017-03-13 DK DK17710528.5T patent/DK3433369T3/da active
- 2017-03-13 EP EP17710528.5A patent/EP3433369B1/en active Active
- 2017-03-13 ES ES17710528T patent/ES2784711T3/es active Active
- 2017-03-13 ES ES20156693T patent/ES2906807T3/es active Active
- 2017-03-13 CN CN201780019155.1A patent/CN108884473B/zh active Active
- 2017-03-13 SI SI201730212T patent/SI3433369T1/sl unknown
- 2017-03-13 CN CN202210935299.4A patent/CN115927467A/zh active Pending
- 2017-03-13 WO PCT/EP2017/055808 patent/WO2017162460A1/en active Application Filing
- 2017-03-13 HR HRP20220044TT patent/HRP20220044T1/hr unknown
- 2017-03-13 SI SI201731043T patent/SI3701959T1/sl unknown
- 2017-03-13 PT PT177105285T patent/PT3433369T/pt unknown
- 2017-03-13 PT PT201566932T patent/PT3701959T/pt unknown
- 2017-03-13 AU AU2017236239A patent/AU2017236239B2/en active Active
- 2017-03-13 HU HUE17710528A patent/HUE050350T2/hu unknown
- 2017-03-13 MX MX2018011383A patent/MX2018011383A/es unknown
- 2017-03-13 RS RS20220067A patent/RS62864B1/sr unknown
- 2017-03-13 CA CA3017272A patent/CA3017272A1/en active Pending
- 2017-03-13 EP EP20156693.2A patent/EP3701959B1/en active Active
- 2017-03-13 US US16/086,157 patent/US11168337B2/en active Active
- 2017-03-13 PL PL20156693T patent/PL3701959T3/pl unknown
- 2017-03-13 BR BR112018068381A patent/BR112018068381A2/pt active Search and Examination
- 2017-03-13 JP JP2018549313A patent/JP7121443B2/ja active Active
- 2017-03-13 HU HUE20156693A patent/HUE059139T2/hu unknown
- 2017-03-13 PL PL17710528T patent/PL3433369T3/pl unknown
- 2017-03-13 DK DK20156693.2T patent/DK3701959T3/da active
- 2017-03-13 RU RU2018131966A patent/RU2748892C2/ru active
- 2017-03-13 LT LTEP20156693.2T patent/LT3701959T/lt unknown
-
2018
- 2018-08-17 ZA ZA201805519A patent/ZA201805519B/en unknown
- 2018-08-26 IL IL261379A patent/IL261379B/en unknown
-
2019
- 2019-02-01 HK HK19101854.2A patent/HK1259449A1/zh unknown
-
2021
- 2021-10-05 US US17/494,601 patent/US20220033852A1/en active Pending
-
2022
- 2022-01-26 CY CY20221100063T patent/CY1125086T1/el unknown
- 2022-03-03 IL IL291100A patent/IL291100B2/en unknown
- 2022-08-02 JP JP2022123058A patent/JP7465310B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2018011383A (es) | Replicon de arn para la expresion genica versatil y eficiente. | |
| MX2018011384A (es) | Arn de replicacion en trans. | |
| SA518400424B1 (ar) | جزيئات الجسم المضاد لعلاج السرطان | |
| MX2020006117A (es) | Integracion dirigida de acidos nucleicos. | |
| MX2019004499A (es) | Sistemas de replicón de virus recombinante y usos de estos. | |
| EP4241784A3 (en) | Artificial nucleic acid molecules for improved protein expression | |
| MX2020009514A (es) | Anticuerpos anti-claudina 18.2 (cldn18.2). | |
| PH12018501628A1 (en) | Optimized factor viii genes | |
| PH12014502767A1 (en) | Interleukin-2 fusion proteins and uses thereof | |
| MY187542A (en) | Carbohydrate degrading polypeptide and uses thereof | |
| MX2016003945A (es) | Composiciones y formulaciones para la prevencion y tratamiento de la diabetes y la obesidad y los metodos de produccion y uso en el control de la glucosa y calorias. | |
| PH12015500284A1 (en) | Interleukin-10 fusion proteins and uses thereof | |
| EA201491470A1 (ru) | Композиции фактора viii и способы получения и использования подобных | |
| MX2018011542A (es) | Moleculas biespecificas de celulas t activadas por proteasas. | |
| MX2019000805A (es) | Variantes de serinproteasa y polinucleotidos que las codifican. | |
| BR112016020517A2 (pt) | método de produção de lipídeo através da utilização de ss-cetoacil-acp sintase | |
| BR112016030326A2 (pt) | ?poliepítopo quimérico, polinucleotídeo, vetores, célula, partículas de vírus, composição imunogênica, método para prevenir e/ou tratar infecções e método de produção de partículas de mv? | |
| MX2017011189A (es) | Dsba y dsbc ultrapurificado y métodos para elaborarlos y utilizarlos. | |
| BR112017027048A2 (pt) | processo para extração de pectina e uso da pectina | |
| MX2018015298A (es) | Metodo para estabilizar proteinas. | |
| IN2015DN03206A (es) | ||
| MX2016011465A (es) | Drimenol-sintasas y metodos para producir drimenol. | |
| MX2016011970A (es) | Metodo para la permeabilizacion termica de una biomasa de microalgas. | |
| WO2016100820A3 (en) | Fgf2 truncations and mutants and uses thereof | |
| CU24445B1 (es) | Procedimiento de preparación de un polvo de macroalgas pardas mediante mezcla y procedimiento de fabricación de objetos rígidos a partir de dicho polvo |